ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1931

NOD2 Mutations Are Associated with Upregulated Type 1 Interferon Gene Expression and Development of Granulomatous Hepatitis in Children with Autoimmune Hepatitis

Esraa Eloseily1, Alexander Valencia2, Astha Malik2, Rebekah Karns2, Cyd Castro Rojas2, Mosab Alquraish2, Rebecca Marsh3, Alexei Grom4 and Alexander Miethke2, 1Division of Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Division of Gastroenterology, Hepatology & Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 3Division of Bone Marrow Transplantation & Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 4Divisions of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

Meeting: ACR Convergence 2022

Keywords: autoimmune diseases, Autoinflammatory diseases, Gene Expression, innate immunity, interferon

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: Pediatric Rheumatology – Clinical Poster III: Other

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Mutations in the gene NOD2 encoding the nucleotide-binding oligomerization domain-containing protein 2 (NOD2) which controls innate responses to LPS have been linked to Blau syndrome or Crohn disease when affecting the NOD or LRR domains, respectively. The role of variants in NOD2 in autoimmune hepatitis (AIH) is unknown.

Methods: Patients with pediatric AIH or PSC were surveyed for variants in NOD2 using research whole exome/genome sequencing (n=55) or clinical NGS (n=8). Purified RNA from circulating leukocytes of patients (n=13, including 3 subject with variants in NOD2) and healthy controls ([HC]; n=6) was subjected to NanoString-based quantitation of expression of 52 genes associated with activation of type 1/2 interferons or NF-kB.

Results: Exome sequencing revealed three heterozygous variants in NOD2 in 5 patients, including the two risk alleles for Crohn disease, p.Gly908Arg and p.Leu1007Profs*2, and p.Asn289Ser, a variant of uncertain significance which localizes upstream of NOD (see table). Patient #1 presented with hepatitis and hypoxemia attributed to hepatopulmonary syndrome. Hepatitis improved with mycophenolate mofetil (MMF), corticosteroids (CS), and later tacrolimus (Tac), but repeat liver biopsy at age 16 showed active granulomatous hepatitis which was accompanied by elevated plasma level for CXCL9 of 3709 (normal< 121 pg/ml), a chemokine induced by IFNg. Patient #2 presented with severe hepatitis, and elevated plasma CXL9 of 9364 pg/ml. On treatment with MMF and CS, LFTs normalized but aplastic anemia developed. Patient #3 presented with hepatitis, Coombs+ hemolytic anemia, and was later diagnosed with SLE. Disease partially responded to MMF and CS. Subject #4 was diagnosed with celiac disease and AIH which was refractory to treatment with azathioprine (AZA), CS, and Tac. Case #5 had AIH which responded promptly to AZA and CS. No patient was diagnosed with IBD. NanoString-based quantitation of interferon and NF-kB gene activation revealed case 5 to segregate with HC in unsupervised analysis, while both subjects with the p.Gly908Arg mutation displayed upregulation of the genes CXCL10, EPSTI1, GBP1, IFIT2, and RTP4 compared with other AILD patients and HC.

Conclusion: NOD2 mutations affecting the LRR domain are associated with granulomatous hepatitis, extrahepatic immune dysregulation, and steroid refractory AIH. Whether upregulation of interferon responses in these patients requires alternative treatments needs further investigations.

Supporting image 1

Demographics, genetic mutations, immune evaluation, liver enzymes and direct bilirubin levels of the 5 patients


Disclosures: E. Eloseily, None; A. Valencia, None; A. Malik, None; R. Karns, None; C. Castro Rojas, None; M. Alquraish, None; R. Marsh, None; A. Grom, Sobi, Novartis; A. Miethke, None.

To cite this abstract in AMA style:

Eloseily E, Valencia A, Malik A, Karns R, Castro Rojas C, Alquraish M, Marsh R, Grom A, Miethke A. NOD2 Mutations Are Associated with Upregulated Type 1 Interferon Gene Expression and Development of Granulomatous Hepatitis in Children with Autoimmune Hepatitis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/nod2-mutations-are-associated-with-upregulated-type-1-interferon-gene-expression-and-development-of-granulomatous-hepatitis-in-children-with-autoimmune-hepatitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/nod2-mutations-are-associated-with-upregulated-type-1-interferon-gene-expression-and-development-of-granulomatous-hepatitis-in-children-with-autoimmune-hepatitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology